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In vivo magnetic resonance imaging (MRI) of the heart
with gadolinium-based contrast agents has been performed
since the mid-1980s (1). A major limitation of the initial
techniques was insufficient image contrast between normal
and infarcted myocardium. Recently, a number of studies
have demonstrated the effectiveness of a new segmented
inversion recovery MRI pulse sequence for differentiating
normal from infarcted myocardium with signal intensity
differences of nearly 500% (2,3). This new technique for
gadolinium-enhanced MRI has been shown to be effective
in identifying the presence, location, and extent of myocar-
dial infarction in both the acute and chronic settings (3–5).
Furthermore, this technique has been validated in animal
models of ischemic injury (2,6,7), provides scar size mea-
surements that are closely correlated with positron emission
tomography in patients with ischemic cardiomyopathy (8),
and provides results superior to single-photon emission
computed tomography perfusion imaging in patients with
small myocardial infarctions (9).
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Both acute and chronic infarcts are visualized on contrast
MRI as bright or “hyperenhanced” zones. Normal myocar-
dium, as well as injured but viable myocardium, such as
stunned or hibernating myocardium, does not display hy-
perenhancement (2,5,10). The mechanism of hyperen-
hancement is believed to be due to tissue accumulation of
gadolinium, possibly because of differences in contrast
distribution volume (7,11). Clinically used gadolinium con-
trast media are “inert” extracellular agents that cannot cross
intact sarcolemmal membranes (12). Because tissue volume
in normal myocardium is predominantly intracellular
(75% to 80% [13]), the distribution volume of gadolinium
is normally quite low. In the setting of acute necrosis,
gadolinium will be able to passively diffuse across ruptured
myocyte membranes into the intracellular space, which will
lead to significant increases in gadolinium concentration at
the tissue level. In the setting of collagenous scar, the
interstitial space is expanded compared with the interstitial
space between densely packed living myocytes that is char-
acteristic of normal myocardium. In this situation, there will
also be increased gadolinium concentration at the tissue
level. Concerning tissue substrates for myocardial hyperen-
hancement, it has been postulated that it is the absence of
viable myocytes that leads to myocardial hyperenhancement
rather than any inherent properties that are specific for
acutely necrotic tissue, collagenous scar, or other forms of
nonviable tissue (14).
Does MRI hyperenhancement represent replacement
scarring in hypertrophic cardiomyopathy (HCM)?
Recently, gadolinium-enhanced MRI was performed in 21
patients with HCM (15). In these patients the maximum
left ventricular (LV) end-diastolic wall thickness averaged
25  8 mm, and they had preserved LV ejection fraction
(70  11%). Hyperenhancement was found in the majority
(81%) of patients, with hyperenhancement mass on average
8  9% of LV mass. The pattern of hyperenhancement was
peculiar. Hyperenhancement occurred only in hypertro-
phied regions, was patchy with multiple foci, and predom-
inantly involved the middle third of the ventricular wall.
Additionally, all patients with hyperenhancement had in-
volvement at the junctions of the interventricular septum
and the right ventricular free wall (Fig. 1A). The direct
comparison of gadolinium MRI to histopathology has not
yet been performed in HCM. However, given the MRI-
histopathologic correlations described here, and the fact that
these patients were predominantly asymptomatic without
any recent cardiac events, hyperenhanced regions were
thought to represent scarred myocardium. Several necropsy
studies have demonstrated that myocardial scarring is com-
mon in HCM (16–21). Similar to the pattern of hyperen-
hancement, the pattern of scarring in these studies was
distinct from that seen in ischemic heart disease. For
instance, scarring did not correspond to any particular
epicardial coronary artery distribution and was often limited
to the mid-wall or subepicardium (16–19,21). Moreover,
Kuribayashi and Roberts (21) demonstrated in a necropsy
study of patients with HCM that the junctions of the
interventricular septum and right ventricular free walls are
the locations where myocardial scarring (along with myo-
cardial disarray) is most prominent. The similarity between
hyperenhancement by MRI and myocardial scarring by
pathology is demonstrated in Figure 1. The locations of
hyperenhancement in the two asymptomatic living patients
(Fig. 1A) are remarkably similar to the locations of scarring
in the reproduced pathology figures from two different
HCM patients studied at necropsy after sudden death (Fig.
1B) (16,20).
Replacement scarring represents only one type of myo-
cardial fibrosis. For example, “plexiform fibrosis” refers to a
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unique type of interstitial fibrosis that is characteristic of
myocardium exhibiting myocardial fiber disarray (22).
Therefore, it is possible that myocardial hyperenhancement
in HCM is not specific for replacement scarring since,
theoretically, gadolinium distribution volume can be in-
creased in the setting of all forms of myocardial fibrosis.
This is unlikely for two reasons. First, it should be noted
that contrast MRI is sensitive to regional differences in
gadolinium accumulation rather than an overall increase
because the technique depends on the ability to “null” signal
from “remote” (presumably normal) myocardium. There-
fore, cardiac disorders that lead to focal regions of fibrosis
will hyperenhance, whereas disorders that lead to global
changes such as diffuse interstitial fibrosis will not. As an
example of this concept, we have found that patients with
idiopathic dilated cardiomyopathy, a group in whom diffuse
interstitial fibrosis is common but grossly visible scarring is
rare (23), generally do not exhibit hyperenhancement (4).
Second, it should be noted that the voxel resolution of
contrast MRI is approximately 1.9 mm by 1.4 mm by 6 mm.
The histopathologic analogue is fibrosis visible to the naked
eye, which is, to paraphrase Anderson et al. (22), “almost
certainly the result of replacement of irreversibly damaged
myocardium and can be termed a gross or macroscopic scar.”
Although it is possible that partial or incomplete hyperen-
hancement may result from regions with increased intersti-
tial fibrosis without replacement fibrosis, it is improbable
that hyperenhancement of the quality or intensity seen in
Figure 1 occurs without macroscopic scarring.
Is there a link between myocardial scarring and prema-
ture cardiac death? The study by Moon et al. (24) in this
issue of the Journal adds further information. The investi-
Figure 1. Comparison between in vivo gadolinium enhanced magnetic resonance images (MRI) in two patients from reference 15 (A) with reproduced
pathology figures from two different patients with hypertrophic cardiomyopathy studied at necropsy after sudden death (B). Arrows point to regions of
hyperenhancement on magnetic resonance imaging or regions of scar on pathology. Panel B is reproduced with permission from Roberts CS, Roberts WC.
Morphologic features. In: Zipes DP, Rowlands DJ, editors. Progress in Cardiology. Vol. 2/2. 1989:3–22; and Basso et al. Hum Pathol 2000;31:988–98.
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gators report on contrast MRI findings in 53 patients with
HCM. Overall, hyperenhancement (scarring) was found in
79% of patients, a figure quite similar to that found by
Choudhury et al. (15). This study, however, is the first to
compare contrast MRI findings to known clinical risk
factors for premature cardiac death. For instance, 18 pa-
tients had two or more clinical risk factors for sudden death
and 9 patients had adverse LV remodeling with progressive
wall thinning and cavity dilation. When the entire cohort
was considered, the authors observed increased extent of
hyperenhancement in patients with two or more risk factors
for sudden death (15.7% vs. 8.6% of LV mass, p  0.02).
This finding remained significant when the patients with
LV remodeling were removed from the analysis (n  44,
p  0.02). Within the group of patients that had serial
echocardiograms performed for five or more years (n  34),
the occurrence of LV remodeling was also associated with
increased extent of hyperenhancement (28.5% vs. 8.7% of
LV mass, p  0.001). This finding remained significant
when patients with two or more risk factors for sudden
death were removed from the analysis (n  20, p  0.04).
These results in living patients are consistent with data
from necropsy studies. Tanaka et al. (25), in a small study of
10 patients with HCM, observed that patients who died
suddenly had a larger amount of myocardial fibrosis than
those who died from noncardiac causes (13  3% vs. 6 
3% of LV mass, p  0.05). Basso et al. (16) evaluated 19
patients with HCM under the age of 36 years who died
suddenly. Although only a single transverse (short-axis)
section was evaluated for the presence and extent of scar-
ring, septal scars were found in 11 patients (58%), and these
were large, forming 10% to 28% of the septal area. Addi-
tionally, the extent of scarring was positively correlated with
the magnitude of LV hypertrophy, one of the established
clinical risk factors for sudden death (26). Varnava et al. (19)
evaluated 72 patients with HCM who either died suddenly
or progressed to end-stage heart failure (n 22). This study
focused primarily on microscopic evaluation of myocyte
disarray, fibrosis, and small-vessel disease. Macroscopic
evaluation was limited; nonetheless, the extent of replace-
ment scarring was associated with LV hypertrophy and
cavity dilation. The authors comment, “As fibrosis but not
disarray increases with increasing heart weight, it is likely that
the mechanism of sudden death in these patients is related to
marked fibrosis and scarring, rather than to disarray.”
It has recently been established that ventricular tachycar-
dia (VT) or ventricular fibrillation (VF) is the principal
mechanism of sudden death in patients with HCM (27).
Ventricular tachyarrhythmias are also a predominant cause
of sudden death in patients with chronic coronary artery
disease (CAD) (28). Although scarred myocardium is an
established anatomic and electrophysiologic substrate for
the occurrence of ventricular tachyarrhythmias and sudden
death in patients with CAD (28,29), its role in HCM is less
clear. Scarred myocardium, of course, represents healed
infarction in the setting of ischemic heart disease. In HCM,
even in the absence of significant epicardial coronary dis-
ease, scarred myocardium may still be the end result of
ischemia, leading to myocardial necrosis. Several studies
have reported increased numbers of structurally abnormal
intramural coronary arteries within areas of scarred myocar-
dium, and a causal role for these arteries in producing
ischemia has been postulated (18).
The setting of healed infarction leads to “… areas of
abnormal conduction and refractoriness, heterogeneity of con-
duction and refractoriness, enhanced automaticity, and areas of
inexcitability, all of which are potentially arrhythmogenic” (28).
Evidence for slowed and fragmented intraventricular con-
duction as seen in patients with ischemic heart disease has
also been observed in patients with HCM, and these
observations have been associated with risk for sudden death
(30,31). Slowed conduction in HCM, although attributed
to potential electrophysiologic effects of myocardial disarray,
may simply reflect the substrate of myocardial scarring as in
ischemic heart disease.
However, programmed ventricular stimulation performed
in patients with HCM only rarely induces monomorphic
VT (32). Other rhythms such as polymorphic VT and VF
are induced more frequently, but are thought to be nonspe-
cific (33). In this regard, it is interesting to note that patients
with CAD who present with sudden death are less likely to
have inducible monomorphic VT than those that present
with hemodynamically tolerated VT. Additionally, patients
who present with sudden death generally have less extensive
infarction, less frequent incidence of LV aneurysm, higher
ejection fractions, and fewer abnormal electrograms than
those who present with tolerated VT (29). It is believed that
patients who present with sudden death have an anatomic
substrate that is qualitatively similar but quantitatively
smaller than those who present with tolerated VT (28). This
“intermediate substrate” is sufficient to produce rapid ma-
lignant ventricular arrhythmias but is not extensive enough
to support sustained uniform VT (28). In an analogous
fashion, one could speculate that various subgroups of
patients with HCM also represent different points in the
continuum of abnormal electrophysiologic substrates. In the
majority of patients with HCM, those with normal to
supranormal LV ejection fraction and minimal or no scar-
ring (15), there will be insufficient abnormal substrate to
produce malignant ventricular arrhythmias. A small per-
centage of patients with normal ejection fraction, however,
will have sufficient scarring, albeit in a patchy, multifocal
fashion (15), to support smaller re-entrant circuits and thus
be at risk for rapid malignant arrhythmias. Conversely, these
patients will have insufficient abnormal substrate to repro-
ducibly develop sustained uniform VT during programmed
stimulation. Finally, in the very few patients with adverse
LV remodeling and systolic dysfunction, these patients will
have sufficient scarring to develop both spontaneous malig-
nant ventricular arrhythmias and sustained uniform VT
during programmed stimulation.
The results of Moon et al. (24) demonstrate that patients
1570 Kim and Judd JACC Vol. 41, No. 9, 2003
Editorial Comment May 7, 2003:1568–72
with adverse remodeling had the greatest amount of hyper-
enhancement (scarring). In fact, the patient with least
amount of hyperenhancement in this group had hyperen-
hancement of over 15% of the LV myocardium. It is
perhaps not surprising that significant hyperenhancement
was found in both patients with risk factors for sudden
death as well as those with adverse remodeling. Continuing
our analogy with CAD, scarring of course is often found in
those with CAD that die suddenly as well as those that die
from progressive heart failure. In both HCM and CAD, it
is probable that appropriate triggers (systemic hypotension,
physical exertion, and so on) are required in addition to the
electrophysiologic substrate for the occurrence of malignant
ventricular tachyarrhythmias.
The associations between hyperenhancement and clinical
risk factors for premature cardiac death demonstrated by
Moon et al. (24) represent an important first step. However,
it is apparent that there is a wide range in the extent of
hyperenhancement within patient subgroups and there is
clearly overlap between groups. With this in mind, it is
important to note that using two or more clinical risk factors
as a marker of sudden death provides a sensitivity of only
45% and a positive predictive accuracy of 23% (34). Ulti-
mately, of course, the independent prognostic value of
gadolinium-enhanced MRI in assessing premature cardiac
death will need to be determined. Given the relatively rare
occurrence of HCM in the general population and the
relatively benign nature of this disease, a prospective study
in a sufficient patient population may initially appear pro-
hibitive. Conversely, gadolinium-enhanced MRI is a sim-
ple, reproducible technique (35), and the number of centers
able to perform this technique is growing exponentially. The
important data by Moon et al. (24) indicate that assessment
of the prognostic value of gadolinium-enhanced MRI in
HCM is warranted.
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